دورية أكاديمية
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies
العنوان: | Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies |
---|---|
المؤلفون: | Richard Burt, Dana Warcel, Adele K. Fielding |
المصدر: | Human Vaccines & Immunotherapeutics, Vol 15, Iss 3, Pp 594-602 (2019) |
بيانات النشر: | Taylor & Francis Group, 2019. |
سنة النشر: | 2019 |
المجموعة: | LCC:Immunologic diseases. Allergy LCC:Therapeutics. Pharmacology |
مصطلحات موضوعية: | blinatumomab, acute lymphoblastic leukaemia, b-cell non hodgkin lymphoma, immunotherapeutics, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950 |
الوصف: | Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient’s T cells with CD19-expressing tumour cells. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin’s Lymphoma including in patients who are refractory to chemotherapy. This review summarises the development and design of Blinatumomab, the outcome of clinical studies demonstrating its efficacy and how to manage the administration, practically, including relevant toxicities. We compare and contrast it to other emerging agents for treatment of B-cell malignancies. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2164-5515 2164-554X 21645515 |
العلاقة: | https://doaj.org/toc/2164-5515Test; https://doaj.org/toc/2164-554XTest |
DOI: | 10.1080/21645515.2018.1540828 |
الوصول الحر: | https://doaj.org/article/bc96208bfea24f84a57ed96f6b758bd0Test |
رقم الانضمام: | edsdoj.bc96208bfea24f84a57ed96f6b758bd0 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 21645515 2164554X |
---|---|
DOI: | 10.1080/21645515.2018.1540828 |